Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab (AK104) plus lenvatinib for recurrent hepatocellular carcinoma
ChiCTR2500107110Phase 4Completed
- Sponsor
- Army Medical University
- Start
- Aug 2025
- Modality
- Small Molecules, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cadonilimab and lenvatinib in hepatocellular carcinoma (HCC), sponsored by Army Medical University. Primary endpoint: Progression-free survival (PFS). Started Aug 2025; status: completed.
02
Drugs
cadonilimablenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2500107110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500107110.